{"hands_on_practices": [{"introduction": "Effective clinical diagnosis requires a well-designed assay. This first practice simulates the high-level decision-making needed to construct a multi-color immunophenotyping panel for a complex disease like Acute Myeloid Leukemia (AML). By integrating knowledge of cell biology and reagent capabilities, this exercise challenges you to select a combination of markers that can identify the target population and detect the subtle abnormalities critical for diagnosis and monitoring [@problem_id:5233915].", "problem": "A $48$-year-old patient presents with leukocytosis and circulating blasts. Bone marrow aspirate is sent for immunophenotyping on a $3$-laser, $8$-color flow cytometer to evaluate for Acute Myeloid Leukemia (AML). You are asked to propose a single-tube backbone panel that maximizes detection of cellular immaturity and myeloid lineage, while enabling recognition of aberrant antigen expression patterns that can be useful for baseline characterization and future Measurable Residual Disease (MRD) tracking.\n\nStart from the following fundamental principles:\n- Flow cytometry measures fluorescence from antibodies bound to antigens; fluorochrome intensity reflects antigen density per cell. Side scatter (SSC) approximates granularity, and forward scatter (FSC) approximates size. Normal myeloid maturation involves a stereotyped progression of antigen expression.\n- Myeloid blasts typically display low granularity and reduced pan-leukocyte signal compared to mature lymphocytes, such that a CD45 versus SSC plot separates blasts (CD45 dim, SSC low) from mature lymphocytes (CD45 bright, SSC low) and neutrophils (CD45 intermediate, SSC high).\n- Immaturity is commonly captured by CD34, CD117, and human leukocyte antigen DR (HLA-DR); myeloid lineage is commonly supported by cytoplasmic myeloperoxidase (MPO), CD33, and/or CD13; maturation markers such as CD15 or CD11b rise as cells mature.\n- Aberrant immunophenotypes in AML include cross-lineage antigen expression (for example, T or B markers on myeloid blasts), asynchronous maturation (for example, co-expression of immature markers with mature myeloid antigens), over- or under-expression relative to normal maturation trajectories, and absence of expected markers. Robust detection requires comparison to internal normal counterparts and appropriate controls.\n\nYou have a single $8$-color tube available and will analyze fresh bone marrow using a surface plus cytoplasmic staining protocol compatible with MPO detection. Select the option that presents the most appropriate single-tube backbone and a scientifically sound analysis plan to detect aberrancies, under these constraints.\n\nA. Panel: CD45, CD34, CD117, HLA-DR, CD33, myeloperoxidase (MPO), CD7, CD15. Analysis: Gate blasts on CD45 versus SSC (CD45 dim, SSC low), then assess co-expression of immaturity markers (CD34, CD117, HLA-DR) with myeloid markers (CD33, MPO). Detect aberrancies by (i) cross-lineage expression (CD7 on blasts), (ii) asynchronous maturation (CD15 co-expressed with CD34), and (iii) shifts in mean fluorescence intensity relative to internal normal myeloid precursors and mature neutrophils; use fluorescence-minus-one (FMO) controls for thresholding and compensation to correct spectral overlap.\n\nB. Panel: CD45, CD3, CD19, immunoglobulin kappa, immunoglobulin lambda, T-cell receptor alpha-beta, HLA-DR, viability dye. Analysis: Identify blasts primarily by FSC height versus FSC width to exclude doublets, then use scatter patterns to infer myeloid lineage; detect aberrancies from atypical scatter alone without reference to normal antigen trajectories.\n\nC. Panel: CD45, CD34, CD117, HLA-DR, CD13, CD33, CD64, CD14. Analysis: Gate blasts on CD45 versus SSC, then classify aberrancies by applying fixed manufacturer cutoffs for positivity on each marker without comparison to internal normal populations; assume CD34 positivity is required to define blasts in AML.\n\nD. Panel: CD45, CD34, CD117, HLA-DR, CD33, MPO, CD7, CD19. Analysis: Gate blasts on CD45 versus SSC; declare aberrancies present if either CD7 or CD19 is detected on blasts; omit comparison to normal myeloid maturation or assessment of asynchronous maturation due to tube capacity constraints.\n\nSelect the single best option.", "solution": "The user wants me to validate a problem statement regarding the design of a flow cytometry panel for Acute Myeloid Leukemia (AML) diagnosis, and then solve it by selecting the best option among four choices.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n-   **Clinical Setting**: $48$-year-old patient with leukocytosis and circulating blasts.\n-   **Specimen**: Bone marrow aspirate.\n-   **Technique**: $3$-laser, $8$-color flow cytometer.\n-   **Staining**: Single-tube, surface plus cytoplasmic staining protocol compatible with myeloperoxidase (`MPO`) detection.\n-   **Objectives**: The panel must:\n    1.  Maximize detection of cellular immaturity.\n    2.  Maximize detection of myeloid lineage.\n    3.  Enable recognition of aberrant antigen expression patterns for baseline characterization and future Measurable Residual Disease (MRD) tracking.\n-   **Stated Fundamental Principles**:\n    -   Flow cytometry measures antigen density via fluorescence; `SSC` approximates granularity, `FSC` approximates size. Normal myeloid maturation is a stereotyped process.\n    -   Myeloid blasts are typically `CD45` dim, `SSC` low. This distinguishes them from mature lymphocytes (`CD45` bright, `SSC` low) and neutrophils (`CD45` intermediate, `SSC` high).\n    -   Immaturity markers: `CD34`, `CD117`, `HLA-DR`.\n    -   Myeloid lineage markers: cytoplasmic `MPO` (`cMPO`), `CD33`, `CD13`.\n    -   Maturation markers: `CD15`, `CD11b` (expression increases with maturation).\n    -   Aberrant immunophenotypes in AML include: cross-lineage expression, asynchronous maturation, over/under-expression relative to normal, and absence of expected markers.\n    -   Analysis requirement: Comparison to internal normal counterparts and use of appropriate controls.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientifically Grounded**: The problem is factually correct and grounded in the established principles of clinical immunophenotyping for hematologic malignancies. The markers described, their typical expression patterns on normal and leukemic cells, and the principles of analysis (e.g., gating on `CD45`/`SSC`, comparing to normal counterparts) are standard of care and well-documented in consensus guidelines (e.g., EuroFlow, ICCS/ESCCA).\n-   **Well-Posed**: The problem is well-posed. It provides clear constraints (one $8$-color tube), specific objectives for the panel, and a set of fundamental principles to be used as the basis for evaluation. This allows for a unique, best-fit solution to be identified among the choices by logically weighing how well each option meets the specified criteria.\n-   **Objective**: The problem is objective. It presents a technical challenge using precise, unbiased scientific language. There are no subjective or opinion-based claims.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. It is scientifically sound, well-posed, and objective, providing a solid foundation for a rigorous analysis of the options. I will proceed with the solution.\n\n### Solution Derivation\n\nThe goal is to construct the most effective $8$-color panel and analysis plan for AML diagnosis and MRD characterization. The panel must contain markers for gating, establishing immaturity and myeloid lineage, and detecting aberrations.\n\n1.  **Gating Marker**: `CD45` is essential. It is the cornerstone for identifying hematopoietic cell populations via a `CD45` versus side scatter (`SSC`) plot. ($1$ slot used).\n2.  **Immaturity Markers**: To maximize detection of immaturity, it is best to include the three key markers mentioned: `CD34`, `CD117`, and `HLA-DR`. AML blasts can be negative for one or more of these, so including all three provides comprehensive coverage. ($1+3=4$ slots used).\n3.  **Myeloid Lineage Markers**: The problem specifies a cytoplasmic staining protocol is used, making cytoplasmic `MPO` (`cMPO`) inclusion feasible. `cMPO` is the most specific lineage marker for myeloid cells. To supplement this, a pan-myeloid surface marker like `CD33` (or `CD13`) is highly useful. Let's include `cMPO` and `CD33`. ($4+2=6$ slots used).\n4.  **Aberrancy Markers**: With two slots remaining, we need to choose markers that best enable the detection of aberrant phenotypes for MRD tracking. The principles list two key types of aberrancy:\n    -   **Cross-lineage expression**: Requires a marker from another lineage. `CD7` (T-cell associated) is a common and prognostically significant aberrant marker in AML.\n    -   **Asynchronous maturation**: Requires comparing an early marker (e.g., `CD34`) to a later maturation marker. `CD15` is an excellent choice, as it is acquired during granulocytic maturation. `CD34+`/`CD15+` co-expression is a classic example of AML-associated asynchrony.\n    -   Therefore, including `CD7` and `CD15` would be a powerful combination to detect two distinct and important types of aberrancy. ($6+2=8$ slots used).\n\n**Optimal Panel**: `CD45`, `CD34`, `CD117`, `HLA-DR`, `MPO`, `CD33`, `CD7`, `CD15`.\n\n**Optimal Analysis Plan**:\n-   Use `CD45` vs `SSC` to identify the `CD45`-dim, `SSC`-low blast population, as well as internal normal control populations (lymphocytes, monocytes, neutrophils, normal myeloid progenitors).\n-   Confirm the blasts are immature (`CD34+`/`CD117+`/`HLA-DR+`) and of myeloid lineage (`cMPO+`/`CD33+`).\n-   Systematically search for aberrancies by comparing the blast population to the normal maturation patterns observed in the same sample. This includes checking for `CD7` expression (cross-lineage), `CD34+`/`CD15+` co-expression (asynchrony), and quantitative differences (over/under-expression) in markers like `CD33`, `CD117`, and `HLA-DR` compared to normal progenitors.\n-   Utilize proper technical controls, such as compensation for spectral overlap and fluorescence-minus-one (FMO) controls to set accurate gates for positivity, which is critical for an $8$-color panel and for defining subtle aberrancies.\n\nNow, let's evaluate each option against this ideal framework.\n\n### Option-by-Option Analysis\n\n**A. Panel: CD45, CD34, CD117, HLA-DR, CD33, myeloperoxidase (MPO), CD7, CD15. Analysis: Gate blasts on CD45 versus SSC (CD45 dim, SSC low), then assess co-expression of immaturity markers (CD34, CD117, HLA-DR) with myeloid markers (CD33, MPO). Detect aberrancies by (i) cross-lineage expression (CD7 on blasts), (ii) asynchronous maturation (CD15 co-expressed with CD34), and (iii) shifts in mean fluorescence intensity relative to internal normal myeloid precursors and mature neutrophils; use fluorescence-minus-one (FMO) controls for thresholding and compensation to correct spectral overlap.**\n\n-   **Panel**: The panel is `CD45`, `CD34`, `CD117`, `HLA-DR`, `CD33`, `MPO`, `CD7`, `CD15`. This matches the optimal panel derived above. It provides comprehensive coverage for gating, immaturity, myeloid lineage, and two distinct forms of aberrancy detection.\n-   **Analysis Plan**: The analysis plan is exemplary. It correctly describes gating, lineage/immaturity assignment, and a multi-pronged approach to detecting aberrancies that is fully consistent with the stated principles, including comparison to internal controls. Crucially, it also mentions the necessary technical controls (`FMO` and compensation) required for high-parameter flow cytometry.\n-   **Verdict**: **Correct**. This option represents the current standard of excellence for a single-tube AML backbone assay.\n\n**B. Panel: CD45, CD3, CD19, immunoglobulin kappa, immunoglobulin lambda, T-cell receptor alpha-beta, HLA-DR, viability dye. Analysis: Identify blasts primarily by FSC height versus FSC width to exclude doublets, then use scatter patterns to infer myeloid lineage; detect aberrancies from atypical scatter alone without reference to normal antigen trajectories.**\n\n-   **Panel**: This panel is designed for B- and T-cell lineage assessment, not for a primary myeloid workup. It is missing essential myeloid markers (`MPO`, `CD33`) and key immaturity markers (`CD34`, `CD117`).\n-   **Analysis Plan**: The analysis plan is scientifically unsound. Doublet discrimination (`FSC-H` vs `FSC-W`) is a data cleaning step, not a primary population identification strategy. Relying on light scatter alone to determine lineage is highly unreliable and imprecise. Ignoring antigen expression trajectories for aberrancy detection directly violates the fundamental principles given.\n-   **Verdict**: **Incorrect**.\n\n**C. Panel: CD45, CD34, CD117, HLA-DR, CD13, CD33, CD64, CD14. Analysis: Gate blasts on CD45 versus SSC, then classify aberrancies by applying fixed manufacturer cutoffs for positivity on each marker without comparison to internal normal populations; assume CD34 positivity is required to define blasts in AML.**\n\n-   **Panel**: This panel is focused on myeloid and monocytic markers. While reasonable, it has a critical omission: cytoplasmic `MPO`, the a definitive myeloid marker. It also lacks a clear cross-lineage marker like `CD7`.\n-   **Analysis Plan**: The analysis plan is severely flawed. (1) Using \"fixed manufacturer cutoffs\" is poor practice; gates must be set relative to internal and/or procedural negative controls. (2) Not comparing to internal normal populations directly contradicts the problem's principles and is a major methodological error. Aberrancy is a *relative* finding. (3) Assuming `CD34` expression is required for blasts is factually incorrect; a significant minority of AML cases are `CD34`-negative.\n-   **Verdict**: **Incorrect**.\n\n**D. Panel: CD45, CD34, CD117, HLA-DR, CD33, MPO, CD7, CD19. Analysis: Gate blasts on CD45 versus SSC; declare aberrancies present if either CD7 or CD19 is detected on blasts; omit comparison to normal myeloid maturation or assessment of asynchronous maturation due to tube capacity constraints.**\n\n-   **Panel**: This is a strong panel, substituting `CD15` (from option A) with `CD19` (a B-cell marker also aberrantly found in AML). It thus includes two cross-lineage markers but omits a dedicated marker for assessing asynchronous granulocytic maturation. This is a valid design choice, although perhaps less balanced than A.\n-   **Analysis Plan**: The analysis plan is deficient. It correctly identifies the utility of `CD7` and `CD19`, but its proposal to \"omit comparison to normal myeloid maturation or assessment of asynchronous maturation\" is a fatal flaw. Such comparison is the cornerstone of modern aberrancy detection, as stated in the problem's principles. The justification \"due to tube capacity constraints\" is false, as shown by option A, which successfully incorporates a marker for asynchrony (`CD15`).\n-   **Verdict**: **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "5233915"}, {"introduction": "A well-designed panel is only as good as its individual components. This exercise focuses on a critical optimization step: antibody titration, where the goal is to find the ideal reagent concentration. You will apply mathematical models of antigen-antibody binding to determine the concentration that maximizes the signal-to-noise ratio, a concept captured by the Staining Index [@problem_id:5234114].", "problem": "A clinical flow cytometry laboratory is optimizing an anti-cluster of differentiation 34 (anti-CD34) fluorochrome-conjugated antibody for a hematopoietic progenitor cell assay. The laboratory will perform an antibody titration and select the operating concentration that maximizes the Staining Index (SI), defined for each antibody concentration $c$ by the core definition\n$$\n\\mathrm{SI}(c) \\equiv \\frac{\\mathrm{MFI}_{\\mathrm{pos}}(c) - \\mathrm{MFI}_{\\mathrm{neg}}(c)}{2\\,\\mathrm{SD}_{\\mathrm{neg}}(c)},\n$$\nwhere $\\mathrm{MFI}_{\\mathrm{pos}}(c)$ is the median fluorescence intensity of the specifically stained CD34-positive population, $\\mathrm{MFI}_{\\mathrm{neg}}(c)$ is the median fluorescence intensity of the fluorescence-negative population (internal negative cells), and $\\mathrm{SD}_{\\mathrm{neg}}(c)$ is the standard deviation (SD) of the negative population’s fluorescence.\n\nThe experimental design will use a serial dilution series that spans the expected optimal range. A practical series for acquisition is $2$-fold dilutions spanning $c \\in \\{2.0, 1.0, 0.5, 0.25, 0.125, 0.0625\\}$ $\\mu\\mathrm{g}/\\mathrm{mL}$, applied to a fixed cell count per tube, with constant staining volume. For each dilution, events are acquired after compensation and gating on viable, single cells; $\\mathrm{MFI}_{\\mathrm{pos}}(c)$ and $\\mathrm{MFI}_{\\mathrm{neg}}(c)$ are computed from the gated histograms and $\\mathrm{SD}_{\\mathrm{neg}}(c)$ is computed for the negative population.\n\nAssume the following well-tested relationships for antibody-fluorochrome probes in flow cytometry under these conditions:\n- Specific binding follows a Langmuir isotherm so that\n$$\n\\mathrm{MFI}_{\\mathrm{pos}}(c) = M_{\\max}\\,\\frac{c}{K + c} + A,\n$$\nwith $M_{\\max}$ the saturation signal from specific binding, $K$ the half-saturation constant, and $A$ the baseline autofluorescence plus instrument offset shared by positive and negative cells.\n- Nonspecific signal on negatives grows approximately linearly with antibody concentration so that\n$$\n\\mathrm{MFI}_{\\mathrm{neg}}(c) = A + k\\,c,\n$$\nwith slope $k$.\n- Over the operating range, the coefficient of variation of the negative population is approximately constant, implying\n$$\n\\mathrm{SD}_{\\mathrm{neg}}(c) = \\gamma\\,\\mathrm{MFI}_{\\mathrm{neg}}(c),\n$$\nfor a constant $\\gamma$.\n\nUse the parameter values $M_{\\max} = 5.0 \\times 10^{4}$, $K = 1.0$ μg/mL, $A = 700$, $k = 2000$ (μg/mL)⁻¹, and $\\gamma = 0.25$. The stock antibody concentration available to the laboratory is $c_{\\mathrm{stock}} = 100$ $\\mu\\mathrm{g}/\\mathrm{mL}$.\n\nStarting only from the definitions and assumptions above, derive the antibody concentration $c^{\\ast}$ that maximizes $\\mathrm{SI}(c)$, and then compute the corresponding dilution factor $x$ defined by the $1{:}x$ dilution of the stock that produces the optimal working concentration, i.e., $x \\equiv c_{\\mathrm{stock}}/c^{\\ast}$ in the staining volume limit where the stock is diluted into a much larger volume. Report the single final number $x$ as the denominator of the $1{:}x$ dilution. Round your final answer to two significant figures. Do not include any units in your final answer.", "solution": "The objective is to find the antibody concentration $c^{\\ast}$ that maximizes the Staining Index, $\\mathrm{SI}(c)$, and then determine the corresponding dilution factor $x$ from a stock solution.\n\nThe Staining Index is defined as:\n$$ \\mathrm{SI}(c) = \\frac{\\mathrm{MFI}_{\\mathrm{pos}}(c) - \\mathrm{MFI}_{\\mathrm{neg}}(c)}{2\\,\\mathrm{SD}_{\\mathrm{neg}}(c)} $$\nThe problem provides models for each term in this expression:\n1.  $\\mathrm{MFI}_{\\mathrm{pos}}(c) = M_{\\max}\\,\\frac{c}{K + c} + A$\n2.  $\\mathrm{MFI}_{\\mathrm{neg}}(c) = A + k\\,c$\n3.  $\\mathrm{SD}_{\\mathrm{neg}}(c) = \\gamma\\,\\mathrm{MFI}_{\\mathrm{neg}}(c) = \\gamma(A + k\\,c)$\n\nSubstituting these models into the definition of $\\mathrm{SI}(c)$:\n$$ \\mathrm{SI}(c) = \\frac{\\left(M_{\\max}\\frac{c}{K+c} + A\\right) - (A + kc)}{2\\gamma(A + kc)} $$\nThe term $A$ in the numerator cancels out:\n$$ \\mathrm{SI}(c) = \\frac{M_{\\max}\\frac{c}{K+c} - kc}{2\\gamma(A + kc)} $$\nTo find the concentration $c^{\\ast}$ that maximizes $\\mathrm{SI}(c)$, we need to find the roots of its derivative, $\\frac{d}{dc}\\mathrm{SI}(c) = 0$. Since $2\\gamma$ is a positive constant, maximizing $\\mathrm{SI}(c)$ is equivalent to maximizing the function $f(c) = \\frac{\\mathrm{SI}(c)}{1/(2\\gamma)}$:\n$$ f(c) = \\frac{M_{\\max}\\frac{c}{K+c} - kc}{A + kc} $$\nWe will find the maximum of $f(c)$ by solving $\\frac{d f}{d c} = 0$. Let $N(c) = M_{\\max}\\frac{c}{K+c} - kc$ and $D(c) = A+kc$. Using the quotient rule for differentiation, $\\left(\\frac{N}{D}\\right)' = \\frac{N'D - ND'}{D^2}$, the condition $\\frac{df}{dc}=0$ simplifies to $N'(c)D(c) - N(c)D'(c) = 0$.\n\nFirst, we compute the derivatives $N'(c)$ and $D'(c)$:\n$$ N'(c) = \\frac{d}{dc}\\left(M_{\\max}\\frac{c}{K+c} - kc\\right) = M_{\\max}\\frac{(K+c)(1) - c(1)}{(K+c)^2} - k = \\frac{M_{\\max}K}{(K+c)^2} - k $$\n$$ D'(c) = \\frac{d}{dc}(A+kc) = k $$\nNow, we set up the equation $N'(c)D(c) = N(c)D'(c)$:\n$$ \\left(\\frac{M_{\\max}K}{(K+c)^2} - k\\right)(A+kc) = \\left(M_{\\max}\\frac{c}{K+c} - kc\\right)k $$\nExpanding the terms:\n$$ \\frac{M_{\\max}K(A+kc)}{(K+c)^2} - kA - k^2c = \\frac{M_{\\max}kc}{K+c} - k^2c $$\nThe term $-k^2c$ cancels from both sides:\n$$ \\frac{M_{\\max}K(A+kc)}{(K+c)^2} - kA = \\frac{M_{\\max}kc}{K+c} $$\nTo eliminate the denominators, we multiply the entire equation by $(K+c)^2$:\n$$ M_{\\max}K(A+kc) - kA(K+c)^2 = M_{\\max}kc(K+c) $$\nExpanding the products:\n$$ M_{\\max}AK + M_{\\max}kKc - kA(K^2+2Kc+c^2) = M_{\\max}kKc + M_{\\max}kc^2 $$\nThe term $M_{\\max}kKc$ cancels:\n$$ M_{\\max}AK - kAK^2 - 2kAKc - kAc^2 = M_{\\max}kc^2 $$\nWe rearrange this into a standard quadratic equation of the form $ac^2+bc+d=0$:\n$$ (M_{\\max}k + kA)c^2 + 2kAKc - (M_{\\max}AK - kAK^2) = 0 $$\nFactoring out common terms gives:\n$$ k(M_{\\max} + A)c^2 + (2kAK)c - AK(M_{\\max}-kK) = 0 $$\nThis is the quadratic equation for the optimal concentration $c=c^{\\ast}$.\n\nNow, we substitute the given parameter values:\n$M_{\\max} = 5.0 \\times 10^{4}$\n$K = 1.0$ $\\mu\\mathrm{g}/\\mathrm{mL}$\n$A = 700$\n$k = 2000$ $(\\mu\\mathrm{g}/\\mathrm{mL})^{-1}$\n\nThe coefficients of the quadratic equation $ac^2+bc+d=0$ are:\n$a = k(M_{\\max} + A) = 2000(50000 + 700) = 2000(50700) = 1.014 \\times 10^8$\n$b = 2kAK = 2(2000)(700)(1.0) = 2.8 \\times 10^6$\n$d = -AK(M_{\\max}-kK) = -700(1.0)(50000 - 2000 \\times 1.0) = -700(48000) = -3.36 \\times 10^7$\n\nThe quadratic equation is:\n$$ (1.014 \\times 10^8)c^2 + (2.8 \\times 10^6)c - (3.36 \\times 10^7) = 0 $$\nWe solve for $c$ using the quadratic formula, $c = \\frac{-b \\pm \\sqrt{b^2-4ad}}{2a}$. Since concentration $c$ must be positive, and $a>0$, $d<0$, the term $-4ad$ is positive, ensuring $\\sqrt{b^2-4ad} > \\sqrt{b^2}=|b|$. We must take the positive sign to obtain a positive root for $c$.\n$$ c^{\\ast} = \\frac{-b + \\sqrt{b^2-4ad}}{2a} $$\nFirst, calculate the discriminant, $b^2-4ad$:\n$b^2 = (2.8 \\times 10^6)^2 = 7.84 \\times 10^{12}$\n$4ad = 4(1.014 \\times 10^8)(-3.36 \\times 10^7) = -1.36224 \\times 10^{16}$\n$b^2 - 4ad = 7.84 \\times 10^{12} - (-1.36224 \\times 10^{16}) = 7.84 \\times 10^{12} + 1.36224 \\times 10^{16}$\n$b^2 - 4ad = 0.000784 \\times 10^{16} + 1.36224 \\times 10^{16} = 1.363024 \\times 10^{16}$\n\nNow, we compute $c^{\\ast}$:\n$$ c^{\\ast} = \\frac{-2.8 \\times 10^6 + \\sqrt{1.363024 \\times 10^{16}}}{2(1.014 \\times 10^8)} $$\n$$ c^{\\ast} = \\frac{-2.8 \\times 10^6 + 1.167486 \\times 10^8}{2.028 \\times 10^8} = \\frac{1.139486 \\times 10^8}{2.028 \\times 10^8} \\approx 0.561877 \\text{ } \\mu\\mathrm{g}/\\mathrm{mL} $$\nThe problem asks for the dilution factor $x$, defined as $x = c_{\\mathrm{stock}}/c^{\\ast}$. The stock concentration is given as $c_{\\mathrm{stock}} = 100$ $\\mu\\mathrm{g}/\\mathrm{mL}$.\n$$ x = \\frac{100 \\text{ } \\mu\\mathrm{g}/\\mathrm{mL}}{0.561877 \\text{ } \\mu\\mathrm{g}/\\mathrm{mL}} \\approx 177.973 $$\nFinally, we round the result to two significant figures. The first two significant digits are $1$ and $7$. The third digit is $7$, so we round up the second digit.\n$$ x \\approx 180 $$\nTo express this unambiguously with two significant figures, we use scientific notation: $1.8 \\times 10^2$.\nThe final answer is the number representing the denominator of the $1{:}x$ dilution.", "answer": "$$\\boxed{1.8 \\times 10^{2}}$$", "id": "5234114"}, {"introduction": "After acquiring data with an optimized panel, the final step is accurate analysis and interpretation. This practice delves into the statistical basis for setting a 'positivity gate' in a multicolor experiment, a process that relies on a Fluorescence-Minus-One (FMO) control. By modeling the background signal, you will learn to quantitatively distinguish true positive events from background noise, a cornerstone of reliable flow cytometry results [@problem_id:5234026].", "problem": "A clinical flow cytometry laboratory is establishing a positivity gate for a single-marker channel in a diagnostic panel. Two controls are acquired on the same instrument with stable settings: an unstained control and a Fluorescence Minus One (FMO) control, where the FMO contains all reagents except the marker of interest. The laboratory operates on linear fluorescence intensity units and seeks to set a gate that controls the background false-positive rate for the marker channel.\n\nAssume the following scientifically standard base and modeling assumptions:\n- The measured fluorescence intensity for a background-only event in a given channel is the sum of two independent additive components: endogenous autofluorescence and multi-parameter spectral spillover/spreading error from other fluorochromes present in the panel.\n- For a fixed instrument configuration, the distribution of background intensities in each control can be approximated by a normal distribution, justified by the Central Limit Theorem acting on many small, independent sources of variation in signal and detector noise.\n- A positivity gate is defined to achieve a specified false-positive rate $\\alpha$ for the chosen background distribution, meaning the gate is placed at the $(1-\\alpha)$ quantile of the relevant background intensity distribution.\n\nYou are provided the following empirically determined summary statistics from large, stable acquisitions:\n- Unstained control (autofluorescence only) has sample mean $120$ arbitrary units (a.u.) and sample standard deviation $30$ a.u.\n- FMO control (autofluorescence plus spillover/spreading from other reagents) has sample mean $180$ a.u. and sample standard deviation $50$ a.u.\n\nThe laboratory requires a background false-positive rate of $\\alpha = 0.01$ for the marker channel. Under the additive and independence assumptions above, estimate the contribution of autofluorescence to the FMO-based positivity threshold and then compute the adjusted gate value on an autofluorescence-subtracted scale, defined as the difference between the FMO gate and the autofluorescence gate. Express the final adjusted gate value in arbitrary units (a.u.) and round your answer to three significant figures.", "solution": "The problem statement is subjected to a rigorous validation procedure before any attempt at a solution is made.\n\n**Step 1: Extract Givens**\n\n- **Model Assumptions:**\n  1. The measured background fluorescence intensity is a sum of two independent, additive random variables: endogenous autofluorescence ($X_A$) and spectral spillover/spreading error ($X_S$). Thus, the FMO intensity is $X_{FMO} = X_A + X_S$.\n  2. The distributions of background intensities are approximated by normal distributions.\n  3. A positivity gate is set at the $(1-\\alpha)$ quantile of the relevant background intensity distribution.\n\n- **Data for Unstained Control (Autofluorescence):**\n  - The distribution is $X_A \\sim N(\\mu_A, \\sigma_A^2)$.\n  - Sample mean $\\mu_A = 120$ a.u.\n  - Sample standard deviation $\\sigma_A = 30$ a.u.\n\n- **Data for FMO Control (Autofluorescence + Spillover/Spreading):**\n  - The distribution is $X_{FMO} \\sim N(\\mu_{FMO}, \\sigma_{FMO}^2)$.\n  - Sample mean $\\mu_{FMO} = 180$ a.u.\n  - Sample standard deviation $\\sigma_{FMO} = 50$ a.u.\n\n- **Required False-Positive Rate:**\n  - $\\alpha = 0.01$.\n\n- **Objective:**\n  - Compute the \"adjusted gate value on an autofluorescence-subtracted scale,\" which is explicitly defined as the difference between the FMO-based positivity gate and the autofluorescence-based positivity gate.\n  - The final answer must be rounded to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\n\n- **Scientific Groundedness:** The model is a standard and well-accepted simplification used in flow cytometry analysis. The use of FMO controls to account for spillover, the assumption of normality for large event counts, and the quantile-based gating strategy are all cornerstones of the field. The provided numerical values are physically plausible. The additive model's consistency is verifiable: for independent variables, $\\sigma_{FMO}^2 = \\sigma_A^2 + \\sigma_S^2$, which implies $\\sigma_S^2 = \\sigma_{FMO}^2 - \\sigma_A^2 = 50^2 - 30^2 = 1600 > 0$. The model is internally consistent.\n- **Well-Posedness:** The problem is mathematically well-posed. All necessary parameters are provided, and the objective is an unambiguously defined quantity. A unique solution exists.\n- **Objectivity:** The problem is stated in precise, quantitative terms, free from subjective language.\n\n**Step 3: Verdict and Action**\n\nThe problem is scientifically sound, self-contained, and well-posed. We may therefore proceed with a formal solution.\n\nThe solution is developed as follows. A positivity gate, $g$, for a background population with intensity $X$ distributed as $N(\\mu, \\sigma^2)$ is set to control the false-positive rate at a level $\\alpha$. This means the gate is placed such that the probability of a background event exceeding the gate is $\\alpha$:\n$$P(X > g) = \\alpha$$\nThis is equivalent to finding the $(1-\\alpha)$ quantile of the distribution. For a normal distribution, this gate can be expressed in terms of the mean $\\mu$, the standard deviation $\\sigma$, and the $(1-\\alpha)$ quantile of the standard normal distribution, $z_{1-\\alpha}$. The gate is given by:\n$$g = \\mu + z_{1-\\alpha} \\sigma$$\nThe problem defines two relevant background populations, each with its own gate.\n\nFirst, the gate for the unstained control (autofluorescence only), denoted $g_A$, is based on the distribution $X_A \\sim N(\\mu_A, \\sigma_A^2)$. Using the given parameters $\\mu_A = 120$ and $\\sigma_A = 30$:\n$$g_A = \\mu_A + z_{1-\\alpha} \\sigma_A = 120 + z_{1-\\alpha}(30)$$\n\nSecond, the gate for the Fluorescence Minus One (FMO) control, denoted $g_{FMO}$, is based on the distribution $X_{FMO} \\sim N(\\mu_{FMO}, \\sigma_{FMO}^2)$. This control represents the true background for a fully stained sample in the channel of interest. Using the given parameters $\\mu_{FMO} = 180$ and $\\sigma_{FMO} = 50$:\n$$g_{FMO} = \\mu_{FMO} + z_{1-\\alpha} \\sigma_{FMO} = 180 + z_{1-\\alpha}(50)$$\n\nThe problem requires a false-positive rate of $\\alpha = 0.01$. We need to find the value of $z_{1-0.01} = z_{0.99}$. This is the value from the standard normal distribution $Z \\sim N(0,1)$ for which the cumulative distribution function is $0.99$. This is a standard statistical value:\n$$z_{0.99} \\approx 2.3263$$\n\nThe problem asks for the \"adjusted gate value,\" which is explicitly defined as the difference between the FMO gate and the autofluorescence gate. Let this quantity be $\\Delta g$.\n$$\\Delta g = g_{FMO} - g_A$$\nSubstituting the expressions for the gates:\n$$\\Delta g = (\\mu_{FMO} + z_{1-\\alpha} \\sigma_{FMO}) - (\\mu_A + z_{1-\\alpha} \\sigma_A)$$\nThis expression can be rearranged by grouping terms:\n$$\\Delta g = (\\mu_{FMO} - \\mu_A) + z_{1-\\alpha} (\\sigma_{FMO} - \\sigma_A)$$\nThis quantity represents the increase in the positivity threshold required to account for the additional background noise (mean shift and increased variance) caused by spillover and spreading from other fluorochromes in the panel.\n\nWe now substitute the given numerical values into this expression:\n$\\mu_{FMO} = 180$\n$\\mu_A = 120$\n$\\sigma_{FMO} = 50$\n$\\sigma_A = 30$\n$z_{1-\\alpha} = z_{0.99} \\approx 2.3263$\n\nThe calculation proceeds as follows:\n$$\\Delta g = (180 - 120) + (2.3263) \\times (50 - 30)$$\n$$\\Delta g = 60 + 2.3263 \\times 20$$\n$$\\Delta g = 60 + 46.526$$\n$$\\Delta g = 106.526$$\n\nThe problem requires the final answer to be rounded to three significant figures. The number $106.526$ has its first three significant digits as $1$, $0$, and $6$. The fourth digit is $5$, which requires rounding up the third digit.\nThus, $106.526$ rounded to three significant figures is $107$.", "answer": "$$\\boxed{107}$$", "id": "5234026"}]}